Audited Financial Results for the Financial Year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals reported revenue of Rs 2,303.97 Lakhs for FY 2025-26, down 9.52% from Rs 2,546.53 Lakhs in the previous year. Net profit declined to Rs 386.52 Lakhs from Rs 428.77 Lakhs, a reduction of approximately 9.85%. The company achieved an EBITDA margin of around 20.4%, similar to the prior year. Operating cash flow turned significantly negative at Rs 1,017.95 Lakhs, primarily due to a large increase in trade receivables of Rs 1,201.84 Lakhs. The company raised equity capital of Rs 2,396.10 Lakhs (net of expenses) through an IPO and invested Rs 1,006.26 Lakhs in property, plant and equipment. The statutory auditor issued an unmodified opinion on the financial statements.
The company shows revenue and profit decline with significant negative operating cash flow despite an IPO infusion. The sharp rise in trade receivables is a concern for cash management. Shareholders should monitor whether the receivables are converted to cash and if revenue growth resumes.